ASCO 2018 | Tepotinib in METex14 skipping alteration NSCLC
Enriqueta Felip, MD, PhD, of Vall d’Hebron University Hospital, Barcelona, Spain, discusses the VISION trial (NCT02864992) of tepotinib for non-small cell lung cancer (NSCLC) patients with MET exon 14 skipping alterations. Dr Felip covers the rationale behind the use of this drug, as well as the cohort and promising results of the study. This interview was recorded at the 2018 American Society of Oncology (ASCO) Annual Meeting, held in Chicago, IL.
Get great new content delivered to your inboxSign up